PatternsRadar
Sign in

ASTRAZENAstraZeneca Pharma India Limited

NSE
6,167.50INR+54.50 (+0.89%)Close · 20 Nov 2026
5 Nov 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹15,419 CrMarket cap
86.8P/E (TTM)
60.2%Delivery

Filings & corporate actions

78 results filed
CSV
Next results · Q3 FY27
Expected 8 Feb 2027 – 11 Feb 2027
Estimate: filed 39–42 days after quarter end, last 5 times
Dividend
₹36.00 per share · last 31 Jul 2026
2026
  • 5 NovresultsResults · Q2 FY27 · standalone+1.3%NSE
  • 16 OctshareholdingShareholding · 30 Sept 2026+0.6%NSE
  • 11 AugresultsResults · Q1 FY27 · standalone-1.8%NSE
  • 31 JuldividendDividend · ₹36.00 per share+0.1%
  • 20 JulshareholdingShareholding · 30 Jun 2026+0.4%NSE
  • 26 MayresultsResults · Q4 FY26 · standalone-3.5%NSE
  • 20 AprshareholdingShareholding · 31 Mar 2026+0.3%NSE
  • 11 FebresultsResults · Q3 FY26 · standalone-2.7%NSE
  • 20 JanshareholdingShareholding · 31 Dec 2025-0.6%NSE

Reaction to results · all yearsrose on day 0 in 34 of 79 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY275 Nov 2026+1.3%-4.2%—6.6×
Q1 FY2711 Aug 2026-1.8%-5.5%-15.0%0.5×
Q4 FY2626 May 2026-3.5%-5.0%-6.4%11.6×
Q3 FY2611 Feb 2026-2.7%-1.8%-7.4%4.5×
Q2 FY267 Nov 2025+0.1%+0.7%-0.4%2.8×
Q1 FY2614 Aug 2025+1.2%-0.6%+8.4%1.1×
Q4 FY2530 May 2025+17.1%+26.2%+11.7%98.2×
Q3 FY2511 Feb 2025+0.7%-6.5%+3.1%3.9×
Q2 FY2514 Nov 2024-5.0%-9.4%-7.4%2.9×
Q1 FY258 Aug 2024+1.2%0.0%+2.6%0.7×
Q4 FY2428 May 2024+0.5%-12.3%-0.7%3.7×
Q3 FY248 Feb 2024-12.9%-16.2%-17.5%12.3×
Q2 FY249 Nov 2023-5.3%-4.9%-4.3%6.3×
Q1 FY2414 Aug 2023+1.0%+5.3%+10.7%8.8×
Q4 FY2330 May 2023+6.5%+4.4%+11.3%21.7×
Q3 FY2310 Feb 2023-1.9%-0.8%-3.8%1.7×
Q2 FY2311 Nov 2022-3.1%-6.3%-2.4%2.6×
Q1 FY239 Aug 2022-0.5%-3.2%-1.8%0.6×
Q4 FY2227 May 2022+12.0%+11.8%+3.6%49.3×
Q3 FY229 Feb 2022+2.2%-1.7%-4.2%1.5×
Q2 FY2210 Nov 2021-0.5%+0.5%+1.8%0.7×
Q1 FY2210 Aug 2021-2.7%-7.4%-5.7%1.3×
Q4 FY2126 May 2021+0.9%-2.3%-5.0%1.3×
Q3 FY219 Feb 2021-3.7%-3.1%-12.2%2.5×
Q2 FY215 Nov 2020-0.3%+0.9%+6.9%0.9×
Q1 FY2111 Aug 2020-1.4%-1.6%+25.2%0.6×
Q4 FY2019 May 2020-10.7%-2.4%+11.1%3.2×
Q3 FY203 Feb 2020-2.8%+1.4%+2.2%1.2×
Q2 FY2012 Nov 20190.0%+5.3%+5.3%1.4×
Q1 FY208 Aug 2019-2.4%-11.2%+5.9%2.3×
Q4 FY1924 May 2019-8.8%-11.8%-11.9%3.1×
Q3 FY1919 Feb 2019+1.3%+11.8%+12.2%0.2×
Q2 FY1926 Nov 2018-7.7%-9.0%-1.9%3.4×
Q1 FY1931 Aug 2018+1.8%+0.3%-15.2%0.9×
Q4 FY1826 May 2018-0.8%-2.0%+24.3%0.2×
Q3 FY1816 Mar 2018-0.6%-3.6%+2.7%0.9×
Q2 FY188 Nov 2017+4.8%+0.5%-3.2%1.0×
Q1 FY1821 Aug 2017-1.6%-1.4%+5.6%0.1×
Q4 FY1727 May 2017-0.9%+0.7%-2.6%0.1×
Q3 FY173 Feb 2017+0.8%-1.3%+1.3%8.4×
Q2 FY1717 Nov 2016+0.4%-0.2%+1.0%0.2×
Q1 FY177 Sept 2016+0.6%-1.5%-6.6%0.1×
Q4 FY1626 May 2016-0.6%-1.2%0.0%1.1×
Q3 FY1613 Feb 2016+2.1%+1.2%+5.3%0.6×
Q2 FY167 Nov 2015-0.9%-3.9%-7.0%0.4×
Q1 FY166 Aug 2015+0.6%-3.8%-1.0%4.7×
Q4 FY1528 May 2015-1.4%-6.0%+21.9%2.8×
Q3 FY1518 Feb 2015-0.5%-4.6%+6.4%0.3×
Q2 FY1524 Nov 2014-0.2%-0.8%-4.4%0.5×
Q1 FY1519 Aug 2014+1.0%-3.4%-7.8%1.0×
Q4 FY146 Jun 2014+1.2%+2.6%+6.7%1.1×
Q3 FY1411 Feb 2014-1.9%-1.5%+24.8%2.9×
Q2 FY1415 Nov 2013+0.7%+0.2%-0.3%0.3×
Q1 FY1416 Aug 2013-4.1%+1.1%+1.5%1.7×
Q4 FY134 Jun 2013-2.8%-9.8%-15.9%0.2×
Q3 FY137 Feb 2013-4.9%-10.1%-41.0%2.0×
Q2 FY138 Nov 2012-1.0%-8.4%-5.2%0.7×
Q1 FY1313 Aug 2012+2.6%+10.7%+10.9%2.7×
Q4 FY1223 May 2012+2.7%+2.2%-1.2%1.2×
Q3 FY126 Feb 2012-1.7%-0.2%+25.9%0.2×
Q2 FY1223 Nov 2011-0.4%-1.2%-0.1%0.1×
Q1 FY129 Aug 2011-0.4%+3.1%-1.7%0.3×
Q3 FY118 Feb 2011-1.2%+0.9%-4.8%1.0×
Q2 FY1127 Oct 2010+2.9%+4.6%+6.2%1.2×
Q1 FY1127 Jul 2010+1.6%+1.1%-3.0%0.0×
Q4 FY1026 Apr 2010-3.0%-5.7%-12.0%1.1×
Q3 FY1023 Feb 2010-2.9%-2.6%-4.4%0.9×
Q2 FY1027 Oct 2009-4.7%-0.7%-5.0%1.6×
Q1 FY1027 Jul 2009+3.8%+10.0%+36.8%5.7×
Q4 FY0923 Apr 2009+1.2%-2.0%+17.7%0.2×
Q3 FY0918 Feb 2009-2.7%-1.8%+3.7%1.0×
Q2 FY0923 Oct 2008-8.7%-7.9%-7.9%1.3×
Q1 FY0929 Jul 2008+11.6%+22.4%+20.4%14.2×
Q4 FY0828 Apr 2008+0.2%-5.9%-6.3%0.4×
Q3 FY0825 Feb 2008+9.4%+12.2%+3.4%1.0×
Q2 FY0826 Oct 2007+5.4%-2.2%-6.0%1.2×
Q1 FY0826 Jul 2007-4.5%-6.7%-12.0%1.1×
Q4 FY0730 Apr 2007+3.0%-2.4%-8.3%—
Q3 FY0723 Feb 2007————
Average-0.3%-1.1%+0.7%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+30.4%
Profit YoY+15.0%
Interest cost YoY+189.4%
Revenue QoQ+6.8%
Profit QoQ+64.3%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+32.4%+31.6%+30.4%+27.1%+0.2%+18.0%
Profit+47.3%+5.2%+17.9%+20.3%-5.5%+13.2%

Key data

Open6,110.00
Day range6,064.00 – 6,214.00
52-week range5,640.00 – 9,469.50
From 52w high-34.9%
RSI (14)46.6
ATR (14)216.31
Volume10.4K
Avg volume (20D)14.1K
Rel volume0.74×
Volatility (1Y)23.0%
Turnover₹6.4Cr
Traded value (NSE)₹6.4Cr
VWAP6,154.49
SMA 50 / 2006,273.11 / 7,767.10
Price band20%

Delivery percentage

Latest · 20 Nov 202660.2%
20-day avg48.5%
1-year avg50.0%
Percentile (own history)74th
Range2.6–98.9%
Sessions3,629

Over the last 20 sessions ASTRAZEN settled 48.5% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 50.0%. The latest session ranks higher than 74% of the 3,629 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.58%
Dividend, trailing 12M₹36.00
Paid every year for8 yr
Shareholders30.4K · +3.6% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy774 days ago

Performance returns

1D1W1M3M6M1Y
Price+0.89%+2.25%+1.09%-17.84%-28.20%-32.62%

Valuation

Market cap₹15,419 Cr
Market cap (NSE)₹15,419 Cr
Free-float cap₹3,855 Cr
P/E (TTM)86.8
P/E (NSE)86.0
EPS (TTM)71.09
P/B17.5
Net margin (TTM)6.8%
Other income / PBT14.5%
ROE21.2%
Debt / equity0.00
Shares outstanding2.50Cr
Listed4 May 2001

Ownership

Promoter75.00%
Promoter Δ QoQ0.00 pp
Public25.00%
FII2.64%
DII7.09%
Pledged0.00%

Quarterly results · standalone

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)611.6578.6682.8729.1
YoY chg+38.9%+20.4%+29.7%+30.4%
Net profit (₹ Cr)32.644.937.962.3
YoY chg+5.6%-23.0%-32.1%+15.0%
Net margin5.3%7.8%5.6%8.5%
EPS13.040.000.000.00

Shareholding over time

By quarter

30 Sept 2026 · promoter 75.00% · public 25.00%
30 Sept 2021: promoter 75.00%31 Dec 2021: promoter 75.00%31 Mar 2022: promoter 75.00%30 Jun 2022: promoter 75.00%30 Sept 2022: promoter 75.00%31 Dec 2022: promoter 75.00%31 Mar 2023: promoter 75.00%30 Jun 2023: promoter 75.00%30 Sept 2023: promoter 75.00%31 Dec 2023: promoter 75.00%31 Mar 2024: promoter 75.00%30 Jun 2024: promoter 75.00%30 Sept 2024: promoter 75.00%31 Dec 2024: promoter 75.00%31 Mar 2025: promoter 75.00%30 Jun 2025: promoter 75.00%30 Sept 2025: promoter 75.00%31 Dec 2025: promoter 75.00%31 Mar 2026: promoter 75.00%30 Jun 2026: promoter 75.00%30 Sept 2026: promoter 75.00%
2021-092026-09
  • Promoter
  • Public and others
Promoter
75.00%
Public
25.00%
Promoter change
0.00 pp
Filed
16 Oct 2026
FII
2.64%
DII
7.09%
Promoter pledged
0.00%

Who the public is

Mutual funds
7.01%

+1.00 pp QoQ

Insurance
0.00%

0.00 pp QoQ

FPI
2.64%

-0.04 pp QoQ

Retail ≤ ₹2L
7.70%

+0.05 pp QoQ

HNI > ₹2L
5.12%

-0.99 pp QoQ

NRI
0.36%

0.00 pp QoQ

Bodies corporate
1.05%

-0.03 pp QoQ

Shareholders
30,408

+3.6% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
AstraZeneca Pharmaceuticals ABPromoter · Corporate75.00%
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMALL CAP FUND(VARIOUS SCHEMES)Mutual fund2.90%
TEJAS BHALCHANDRA TRIVEDIIndividual2.30%
ICICI PRUDENTIAL - VARIOUS SCHEMESMutual fund2.18%
SHIVANI T. TRIVEDIIndividual1.72%
BANDHAN - VARIOUS SCHEMESMutual fund1.50%
PRASHANT JAINIndividual1.10%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Dividends

since 20 Aug 2019 CSV
Financial yearPaymentsDeclaredAdjusted
FY2026-271₹36.00₹36.00
FY2025-261₹32.00₹32.00
FY2024-251₹24.00₹24.00
FY2023-241₹16.00₹16.00
FY2022-231₹8.00₹8.00
FY2021-221₹2.00₹2.00
FY2020-211₹2.00₹2.00
FY2019-201₹1.00₹1.00
Ex-dateRecord dateDeclaredAdjusted
31 Jul 2026—₹36.00₹36.00
18 Jul 2025—₹32.00₹32.00
5 Jul 2024—₹24.00₹24.00
14 Jul 2023—₹16.00₹16.00
7 Jul 2022—₹8.00₹8.00
18 Aug 2021—₹2.00₹2.00
20 Aug 2020—₹2.00₹2.00
20 Aug 2019—₹1.00₹1.00

Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.

Bulk & block deals · 7 Oct 2024

CSV
9 of 9 deals
By year
DateDealClientQuantityPriceValue
7 Oct 2024Sell · bulkGRAVITON RESEARCH CAPITAL LLP1.25L7,887.16₹98.7Cr
7 Oct 2024Buy · bulkGRAVITON RESEARCH CAPITAL LLP1.25L7,884.41₹98.7Cr
30 Sept 2024Sell · bulkGRAVITON RESEARCH CAPITAL LLP1.27L7,804.96₹99.2Cr
30 Sept 2024Buy · bulkGRAVITON RESEARCH CAPITAL LLP1.27L7,802.00₹99.2Cr
24 Sept 2024Sell · bulkGRAVITON RESEARCH CAPITAL LLP1.31L7,506.36₹98.6Cr
24 Sept 2024Buy · bulkGRAVITON RESEARCH CAPITAL LLP1.31L7,499.17₹98.5Cr
3 Apr 2019Sell · bulkICICI PRUDENTIAL MUTUAL FUND A/C VOLATILITY ADVANTAGE PLAN1.25L2,000.00₹25.0Cr
30 May 2013Buy · bulkCROSSEAS CAPITAL SERVICES PVT. LTD.1.31L844.46₹11.1Cr
30 May 2013Sell · bulkCROSSEAS CAPITAL SERVICES PVT. LTD.1.29L845.78₹10.9Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.

Exchange surveillance

20 Nov 2026
  • P/E > 50 (4 quarters) · since 6 Dec 2024 — P/E above 50 on the last four quarters’ earnings.

Price band: 20% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

Standalone
₹ crore, as filed
By year
 Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27Q2 FY27
Revenue from operations305.8383.2387.5408.0440.3480.5526.3559.1611.6578.6682.8729.1
Other income9.78.78.38.28.016.211.26.25.16.09.215.1
Total income315.4391.9395.9416.2448.3496.6537.6565.3616.7584.6692.0744.2
Total expenses295.0337.5353.5365.1372.7412.5462.5487.2571.6525.3641.0640.8
└ Finance costs0.6(0.1)0.10.30.30.70.70.71.12.02.01.9
└ Depreciation3.73.83.99.39.117.716.62.63.85.65.25.4
Profit before tax20.454.4(15.2)51.042.078.574.772.846.558.150.888.5
Tax expense4.614.9(3.4)12.611.220.218.918.614.013.312.826.2
Net profit15.839.5(11.8)38.430.958.355.854.232.644.937.962.3
EPS6.3215.79-4.7215.3712.3423.3022.3321.6913.0417.9515.1724.93
Net margin5.17%10.30%-3.04%9.42%7.01%12.12%10.61%9.70%5.33%7.76%5.56%8.55%
PBT margin6.67%14.18%-3.91%12.51%9.54%16.33%14.19%13.02%7.61%10.05%7.43%12.14%
Tax rate22.54%27.37%—24.70%26.58%25.77%25.26%25.54%29.97%22.81%25.26%29.56%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 5 Nov 2026.

Balance sheet & cash flow · half-yearly

Standalone
₹ crore, as filed
By year

Balance sheet

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Total assets984.91,101.61,078.01,241.31,518.11,614.61,989.12,191.4
Current assets887.11,007.3932.71,066.51,342.41,447.81,732.21,936.6
└ Cash & equivalents500.3520.1505.6496.5536.1399.4447.7573.8
└ Other bank balances0.10.10.30.30.60.60.91.3
└ Current investments0.00.00.00.00.00.00.00.0
└ Trade receivables107.5129.6153.1149.8184.9220.2213.7285.0
└ Inventories190.2266.8227.9382.0548.5778.61,027.31,035.0
Total equity588.7655.0711.9679.4770.4799.0872.8878.9
└ Attributable to owners588.7655.0711.9679.4770.4799.0872.8878.9
└ Share capital5.05.05.05.05.05.05.05.0
Borrowings0.00.00.00.00.00.00.00.0
└ Current0.00.00.00.00.00.00.00.0
└ Non-current0.00.00.00.00.00.00.00.0
Trade payables227.9278.4198.3316.9456.3550.9782.7975.7
Current liabilities383.9435.5357.1474.8703.0777.4981.81,189.5
Total liabilities396.2446.6366.1562.0747.8815.61,116.31,312.5
Net debt(500.5)(520.3)(505.8)(496.8)(536.7)(399.9)(448.6)(575.1)
Debt / equity0.000.000.000.000.000.000.000.00
Current ratio2.312.312.612.251.911.861.761.63

Cash flow, year to date

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow58.349.492.538.465.4(65.7)(15.1)232.4
└ Capex(8.5)(2.9)(10.8)(0.7)(1.8)(0.3)(3.6)(15.6)
Free cash flow49.846.581.837.863.6(66.0)(18.8)216.8
Investing cash flow18.112.521.715.730.813.518.7(5.5)
Financing cash flow(24.5)(42.2)(44.4)(63.2)(65.6)(84.6)(92.0)(100.8)
└ Dividends paid(20.0)(40.0)(40.0)(60.0)(60.0)(80.0)(80.0)(90.0)
└ Buybacks0.00.00.00.00.00.00.00.0
Net change in cash51.919.869.9(9.0)30.6(136.8)(88.4)126.1

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

ASTRAZEN at a glance

  • ASTRAZEN closed at ₹6,167.5 on 20 Nov 2026, +0.89% on the day, -32.6% over one year, 34.9% below its 52-week high of ₹9,469.5.
  • Delivery was 60.2% of traded quantity on 20 Nov 2026, the 74th percentile of its own 3,629 sessions with a reading (20-session average 48.5%, 1-year average 50.0%).
  • Market capitalisation is ₹15,419 crore at a trailing P/E of 86.8 (trailing EPS ₹71.09).
  • Q2 FY27 results (standalone, filed 5 Nov 2026): revenue ₹729 crore (+30.4% year on year), net profit ₹62 crore (+15.0%); the price moved +1.3% on the first session after.
  • Promoters held 75.00% at 30 Sept 2026, unchanged on the previous filing.
  • Q3 FY27 results are expected between 8 Feb 2027 and 11 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE203A01020
SeriesEQ
Listed4 May 2001
Former symbolsASTRAIDL (until 10 Apr 2007)
Former namesAstra IDL Ltd. (until 19 Jun 2001)
NSE market cap · 17 Nov 2026₹15,420 Cr
Free-float market cap (NSE)₹3,799 Cr
Shares outstanding (NSE)2.50Cr
History from10 Apr 2007
Sessions4,849

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.